120 related articles for article (PubMed ID: 7071946)
1. Serum copper level in non-Hodgkin's lymphomas.
Salvagno L; Pappagallo GL; Chiarion Sileni V; Segati R; Cartei G; Endrizzi L; Paccagnella A; Ongaro G; Bonvicini P; Fiorentino MV
Tumori; 1982 Feb; 68(1):57-62. PubMed ID: 7071946
[TBL] [Abstract][Full Text] [Related]
2. The value of serum copper levels in non-Hodgkin's lymphoma.
Cohen Y; Epelbaum R; Haim N; McShan D; Zinder O
Cancer; 1984 Jan; 53(2):296-300. PubMed ID: 6690011
[TBL] [Abstract][Full Text] [Related]
3. Serum copper levels in non-Hodgkin's lymphoma.
Shah-Reddy I; Khilanani P; Bishop CR
Cancer; 1980 Apr; 45(8):2156-9. PubMed ID: 6989485
[TBL] [Abstract][Full Text] [Related]
4. Serum copper, serum ceruloplasmin, and erythrocyte sedimentation rate measurements in children with Hodgkin's disease, non-Hodgkin's lymphoma, and nonmalignant lymphadenopathy.
Margerison AC; Mann JR
Cancer; 1985 Apr; 55(7):1501-6. PubMed ID: 3978543
[TBL] [Abstract][Full Text] [Related]
5. [Clinical study on serum copper and zinc levels and copper/zinc ratio in malignant lymphoma].
Wu HY
Zhonghua Zhong Liu Za Zhi; 1988 Sep; 10(5):335-8. PubMed ID: 3248498
[TBL] [Abstract][Full Text] [Related]
6. Significance of copper level in serum and routine laboratory parameters in estimation of outspreading of Hodgkin's lymphoma.
Jamakovic M; Baljic R
Med Arch; 2013; 67(3):185-7. PubMed ID: 23848039
[TBL] [Abstract][Full Text] [Related]
7. Serum copper and zinc levels and copper/zinc ratio in pediatric non-Hodgkin's lymphoma.
Gözdaşoğlu S; Cavdar AO; Arcasoy A; Akar N
Acta Haematol; 1982; 67(1):67-70. PubMed ID: 6800204
[TBL] [Abstract][Full Text] [Related]
8. A third generation regimen VACOP-B with or without adjuvant radiotherapy for aggressive localized non-Hodgkin's lymphoma: report from the Italian Non-Hodgkin's Lymphoma Co-operative Study Group.
Santini G; De Souza C; Aversa S; Patti C; Tedeschi L; Candela M; Olivieri A; Chisesi T; Rubagotti A; Centurioni R; Nardi V; Congiu M; Gennaro M; Truini M;
Braz J Med Biol Res; 2004 May; 37(5):719-28. PubMed ID: 15107935
[TBL] [Abstract][Full Text] [Related]
9. Metabolic changes in red blood cells in malignant lymphomas.
De Bellis R; Boulard MR; Kasdorf H; Rodriguez I; Ferrando R; Di Landro J; Ferrari M; Sanguinett CM; Tanzer J
Br J Haematol; 1979 May; 42(1):35-9. PubMed ID: 465359
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors in head and neck non-Hodgkin's lymphoma with special reference to serum lactic dehydrogenase and serum copper.
Hisamitsu S; Shibuya H; Hoshina M; Horiuchi J
Acta Oncol; 1990; 29(7):879-83. PubMed ID: 2261202
[TBL] [Abstract][Full Text] [Related]
11. So-called "Lennert's lymphoma": is it a clinicopathologic entity?
Kim H; Nathwani BN; Rappaport H
Cancer; 1980 Mar; 45(6):1379-99. PubMed ID: 6986978
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of the serum IL-2R level and Ga-67 scan findings in making a differential diagnosis between sarcoidosis and non-Hodgkin's lymphoma.
Kita T; Watanabe S; Yano F; Hayashi K; Yamamoto M; Iwasaki Y; Kosuda S
Ann Nucl Med; 2007 Nov; 21(9):499-503. PubMed ID: 18030581
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors for patients with diffuse large cell or immunoblastic non-Hodgkin's lymphomas: experience of the non-Hodgkin's Lymphoma Pathologic Classification Project.
Simon R; Durrleman S; Hoppe RT; Bonadonna G; Bloomfield CD; Rudders RA; Cheson BD; Berard CW
Med Pediatr Oncol; 1990; 18(2):89-96. PubMed ID: 2406556
[TBL] [Abstract][Full Text] [Related]
14. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
Proctor SJ; Taylor PR; Angus B; Wood K; Lennard AL; Lucraft H; Carey PJ; Stark A; Iqbal A; Haynes A; Russel N; Leonard RC; Culligan D; Conn J; Jackson GH
Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
[TBL] [Abstract][Full Text] [Related]
15. Non-Hodgkin's lymphoma in children.
Pinkel D; Johnson W; Aur RJ
Br J Cancer Suppl; 1975 Mar; 2():298-323. PubMed ID: 1101924
[TBL] [Abstract][Full Text] [Related]
16. The influence of histologic type on the incidence and duration of response in non-Hodgkin's lymphoma.
Herrmann R; Barcos M; Stutzman L; Walsh D; Freeman A; Sokal J; Henderson ES
Cancer; 1982 Jan; 49(2):314-22. PubMed ID: 7032683
[TBL] [Abstract][Full Text] [Related]
17. Non-Hodgkin's lymphoma in northern India. A retrospective analysis of 238 cases.
Garg A; Dawar R; Agarwal V; Rustagi RK; Kochupillai V
Cancer; 1985 Aug; 56(4):972-7. PubMed ID: 4016691
[TBL] [Abstract][Full Text] [Related]
18. Serum lactate dehydrogenase (LDH) as a prognostic index for non-Hodgkin's lymphoma.
Endrizzi L; Fiorentino MV; Salvagno L; Segati R; Pappagallo GL; Fosser V
Eur J Cancer Clin Oncol; 1982 Oct; 18(10):945-9. PubMed ID: 6891644
[TBL] [Abstract][Full Text] [Related]
19. Serum beta 2-microglobulin in malignant lymphoma.
Hagberg H; Killander A; Simonsson B
Cancer; 1983 Jun; 51(12):2220-5. PubMed ID: 6189572
[TBL] [Abstract][Full Text] [Related]
20. [Adriamycin for the treatment of non HOdgkin's lymphomas (author's transl)].
Parlier Y; Gorin NC; Stachowiak J; Najman A; Duhamel G
Sem Hop; 1981 Nov 8-25; 57(41-42):1685-90. PubMed ID: 6272402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
